Bronchoscopic lung-volume reduction with the use of one-way endobronchial valves is a potential treatment for patients with severe emphysema. To date, the benefits have been modest but have been ...

Endobronchial valves that allow air to escape from a pulmonary lobe but not enter it can induce a reduction in lobar volume that may thereby improve lung function and exercise tolerance in ...

Patients who received an endobronchial valve vs. lung volume reduction surgery had significantly heightened odds for mortality and readmission. Risk adjustment is important in future research on ...

CHICAGO, Oct. 22 – Emphysema patients whose lungs are implanted with a pencil eraser-sized, one-way endobronchial valve experience significantly improved measures of lung function and report ...

The global endobronchial valves market is expected to raise from USD 186.99 Million in 2023 to USD 275.83 Million by 2030, at a CAGR of 5.71% during the forecast period. Endobronchial valves are ...

--(BUSINESS WIRE)--Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe ...

GOLD's evidence "A" rating affirms that endobronchial valves, like the Zephyr Valve, are a proven, viable, minimally-invasive treatment option for severe emphysema, a form of COPD Pulmonx Corporation ...

Prominent guidelines 6,7 now recommend bronchoscopic lung volume reduction using endobronchial valves as an alternative treatment option for severe emphysema to more invasive options, such as surgery.

Report Ocean has released a market research report on the Endobronchial Valves industry, covering 150+ countries and analyzing over 1,00000 published and forthcoming reports per year. The report, ...

The new data confirm the long-term benefits of the Zephyr ® Endobronchial Valve (Zephyr Valve), the first minimally invasive procedure to treat patients with severe COPD/emphysema. The study ...